Comparison · NCT00769379-sae
Standard WBI vs WBI, Trastuzumab: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Standard WBI vs WBI, Trastuzumab: serious adverse events. Trial comparisons, record NCT00769379-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00769379-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.00301 | 0.00102 | 0.0088 | wilson | |
| Risk in group 2 | 0.00909 | 0.00479 | 0.0172 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00608 | -0.0144 | 0.00113 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.331 | 0.0898 | 1.22 | log | |
| Odds ratio, group 1 over group 2 | 0.329 | 0.0887 | 1.22 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Standard WBI than on WBI, Trastuzumab | 164 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Standard WBI | standard WBI | 3 | 998 | EG000 |
| Group 2 | WBI, Trastuzumab | WBI, trastuzumab | 9 | 990 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- All Cause Mortality-5 years: Adverse Events: While on study therapy, Day 1 of 1st dose through 30 days after Day 1 of last dose.
Source ClinicalTrials.gov
Trial
- Title
- Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy
- NCT number
- NCT00769379
- Phases
- PHASE3
- Conditions
- Breast Ductal Carcinoma In Situ
- Interventions
- Laboratory Biomarker Analysis, Trastuzumab, Whole Breast Irradiation
- Lead sponsor
- National Cancer Institute (NCI)
- Results first posted
- 2022-02-23
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00769379?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00769379-sae